Physician profile
Farhaad Riyaz
NPI 1063855286
$3,238.19
in general payments reported to CMS, 2019-2025
25 companies · $43.02 in 2025
The $43.02 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,719 · 2020: $637 · 2021: $723 · 2022: $117 · 2025: $43.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $43.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $43.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $703.51 | 2019-2021 | |
| Abbvie INC. | $377.99 | 2019-2022 | |
| Celgene Corporation | $305.09 | 2019 | |
| Pfizer INC. | $226.91 | 2019-2020 | |
| Almirall LLC | $205.30 | 2019 | |
| Dermira, INC. | $159.33 | 2019 | |
| Lilly USA, LLC | $158.69 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $155.88 | 2019-2020 | |
| Galderma Laboratories, L.P. | $153.22 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $103.32 | 2020 | |
| Mayne Pharma Commercial LLC | $95.99 | 2019-2020 | |
| Janssen Biotech, INC. | $93.12 | 2019-2021 | |
| Amgen INC. | $88.27 | 2019-2022 | |
| Leo Pharma INC. | $75.28 | 2019 | |
| Sun Pharmaceutical Industries INC. | $67.32 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solta Medical, A Division of Bausch Health US, LLC | $43.02 | 2025 | Clear+Brilliant |
| Genzyme Corporation | $39.72 | 2020 | |
| Vyne Pharmaceuticals INC. | $37.61 | 2020-2021 | |
| Epi Health, LLC | $35.75 | 2019-2020 | |
| Encore Dermatology INC. | $34.95 | 2019 | |
| Ucb, INC. | $24.36 | 2020 | |
| Taro Pharmaceuticals USA, INC. | $14.85 | 2019 | |
| Biofrontera INC. | $14.42 | 2019 | |
| Mylan Pharmaceuticals INC. | $13.50 | 2019 | |
| Mission Pharmacal Company | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farhaad Riyaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.